• 1
    Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999; 19: 106998.
  • 2
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 22764.
  • 3
    Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 72777.
  • 4
    Taki S. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev 2002; 13: 37991.
  • 5
    Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, Colamonici OR. Cloning and expression of a long form of the beta subunit of the interferon α β receptor that is required for signaling. J Biol Chem 1995; 270: 2160611.
  • 6
    Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60: 22534.
  • 7
    Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, Rogers NC, Smith JM, Stark GR, Gardiner K, Mogensen KE, et al. Mutant U5A cells are complemented by an interferon-α β receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995; 14: 51008.
  • 8
    Pfeffer LM, Basu L, Pfeffer SR, Yang CH, Murti A, Russell-Harde D, Croze E. The short form of the interferon α/β receptor chain 2 acts as a dominant negative for Type I interferon action. J Biol Chem 1997; 272: 110025.
  • 9
    Russell-Harde D, Wagner TC, Perez HD, Croze E. Formation of a uniquely stable Type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon β and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun 1999; 255: 53944.
  • 10
    Russell-Harde D, Pu H, Betts M, Harkins RN, Perez HD, Croze E. Reconstitution of a high affinity binding site for Type I interferons. J Biol Chem 1995; 270: 260336.
  • 11
    Constantinescu SN, Croze E, Wang C, Murti A, Basu L, Mullersman JE, Pfeffer LM. Role of interferon α/β receptor chain 1 in the structure and transmembrane signaling of the interferon α/β receptor complex. Proc Natl Acad Sci USA 1994; 91: 96026.
  • 12
    Abramovich C, Shulman LM, Ratovitski E, Harroch S, Tovey M, Eid P, Revel M. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-α and IFN-β. EMBO J 1994; 13: 58717.
  • 13
    Krishnan K, Pine R, Krolewski JJ. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. Eur J Biochem 1997; 247: 298305.
  • 14
    Duhe RJ, Farrar WL. Structural and mechanistic aspects of Janus kinases: how the two-faced god wields a double-edged sword. J Interferon Cytokine Res 1998; 18: 1-15.
  • 15
    Darnell JE Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998; 18: 54954.
  • 16
    Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999; 11: 4906.
  • 17
    Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 113942.
  • 18
    Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999; 27: 158392.
  • 19
    Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002; 21: 250412.
  • 20
    McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ. Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002; 19: 60915.
  • 21
    Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, et al. Treatment with low-dose interferon-α restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 2001; 7: 284053.
  • 22
    Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002; 16: 7918.
  • 23
    Sanceau J, Boyd DD, Seiki M, Bauvois B. Interferons inhibit tumor necrosis factor-α-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-κB. J Biol Chem 2002; 277: 3576675.
  • 24
    Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4: 5104.
  • 25
    Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, Davis DW, Fidler IJ. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-α. Neoplasia 2001; 3: 15464.
  • 26
    Rani MR, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM. Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α. J Biol Chem 1996; 271: 2287884.
  • 27
    Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001; 107: 5363.
  • 28
    Gil J, Esteban M. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-α receptors. Oncogene 2000; 19: 366574.
  • 29
    Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, Borden EC. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002; 277: 2850411.
  • 30
    Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-β pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002; 169: 84755.
  • 31
    Sanceau J, Hiscott J, Delattre O, Wietzerbin J. IFN-β induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000; 19: 337283.
  • 32
    Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98: 218392.
  • 33
    Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of interferon-α induced apoptosis in malignant cells. Oncogene 2002; 21: 125162.
  • 34
    Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem 1997; 272: 2877985.
  • 35
    Bachmann A, Hanke B, Zawatzky R, Soto U, van Riggelen J, zur Hausen H, Rosl F. Disturbance of tumor necrosis factor α-mediated β interferon signaling in cervical carcinoma cells. J Virol 2002; 76: 28091.
  • 36
    Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-α. Blood 1998; 91: 301727.
  • 37
    Cross JC, Lam S, Yagel S, Werb Z. Defective induction of the transcription factor interferon-stimulated gene factor-3 and interferon α insensitivity in human trophoblast cells. Biol Reprod 1999; 60: 31221.
  • 38
    Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-α. Int J Cancer 2000; 85: 7205.
  • 39
    Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired α-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res 2001; 61: 22616.
  • 40
    Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 3455
  • 41
    Russell-Harde D, Knauf M, Croze E. The use of Zwittergent 3-14 in the purification of recombinant human interferon-β Ser17 (Betaseron). J Interferon Cytokine Res 1995; 15: 317.
  • 42
    Wagner TC, Velichko S, Vogel D, Rani MR, Leung S, Ransohoff RM, Stark GR, Perez HD, Croze E. Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. J Biol Chem 2002; 277: 14939.
  • 43
    Russell-Harde D, Wagner TC, Rani MR, Vogel D, Colamonici O, Ransohoff RM, Majchrzak B, Fish E, Perez HD, Croze E. Role of the intracellular domain of the human type I interferon receptor 2 chain (IFNAR2c) in interferon signaling. Expression of IFNAR2c truncation mutants in U5A cells. J Biol Chem 2000; 275: 239815.
  • 44
    Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD. The human type I interferon receptor. Identification of the interferon β-specific receptor-associated phosphoprotein. J Biol Chem 1996; 271: 331658.
  • 45
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 46
    Picaud S, Bardot B, De Maeyer E, Seif I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002; 22: 45762.
  • 47
    Takayama A, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression of Hu-IFN-αR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. Int J Mol Med 2000; 6: 6217.
  • 48
    Kondo M, Nagano H, Sakon M, Yamamoto H, Morimoto O, Arai I, Miyamoto A, Eguchi H, Dono K, Nakamori S, Umeshita K, Wakasa K, et al. Expression of interferon α/β receptor in human hepatocellular carcinoma. Int J Oncol 2000; 17: 838.
  • 49
    Barthe C, Mahon FX, Gharbi MJ, Faberes C, Bilhou-Nabera C, Hochhaus A, Reiffers J, Marit G. Expression of interferon-α (IFN-α) receptor 2c at diagnosis is associated with cytogenetic response in IFN-α-treated chronic myeloid leukemia. Blood 2001; 97: 356873.
  • 50
    Mejia C, Navarro S, Colamonici OR, Pellin A, Castel V, Llombart-Bosch A. Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma. Oncol Rep 1999; 6: 14953.
  • 51
    Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, Dong Z. Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001; 8: 497505.
  • 52
    Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8: 125870.
  • 53
    Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 2002; 9: 3907.
  • 54
    Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998; 95: 144116.
  • 55
    Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, Liu W, Ellis L, Moscioni AD, Tazelaar J, Fawell S, Qin X, et al. Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001; 108: 8395.